The present disclosure relates to a pharmaceutical composition for preventing or treating an inflammatory disease, comprising a benzofuran-based N-acylhydrazone compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The benzofuran-based N-acylhydrazone compound according to the present disclosure inhibits the activity of NF-κB, which is a major signal transmitter in the inflammatory response, thereby disrupting the initial pathway and process of the biological inflammatory response system and inhibiting inflammatory immune cells and inflammatory cytokines, and thus can prevent and treat various pathological diseases caused by the inflammatory response.

Disclosed are anti-avian pathogenic E. coli (APEC) agents as well as methods of using thereof.

Disclosed are anti-avian pathogenic E. coli (APEC) agents as well as methods of using thereof.

A ketone body composition comprising beta-hydroxybutyrate, related compounds (e.g., 1,3-butanediol), and/or one or more other compounds (e.g., butyrate) may be administered to a non-human animal to raise blood ketones and improve animal health. For example, the ketone body composition can be administered to non-human mammal in order to therapeutically or prophylactically treat one or more conditions selected from obesity, muscle atrophy, body composition, gut health, disease, cancer, epilepsy, seizures, Alzheimer's, oxidative stress, vascular disease, disrupted mitochondria, metabolic decline, cognitive decline, brain function, brain metabolism, brain atrophy, mental acuity, neurological disorders, inflammation, joint health, motor control, memory, or mood. The ketone body composition can be encapsulated, incorporated into a microemulsion or into liposomes, agglomerated, processed using masking/flavoring technologies, and/or otherwise processed so as to improve taste and/or reduce organoleptic reactions from the non-human mammal. Example non-human animals include dogs, cats, horses, cattle, sheep, and pigs.

A ketone body composition comprising beta-hydroxybutyrate, related compounds (e.g., 1,3-butanediol), and/or one or more other compounds (e.g., butyrate) may be administered to a non-human animal to raise blood ketones and improve animal health. For example, the ketone body composition can be administered to non-human mammal in order to therapeutically or prophylactically treat one or more conditions selected from obesity, muscle atrophy, body composition, gut health, disease, cancer, epilepsy, seizures, Alzheimer's, oxidative stress, vascular disease, disrupted mitochondria, metabolic decline, cognitive decline, brain function, brain metabolism, brain atrophy, mental acuity, neurological disorders, inflammation, joint health, motor control, memory, or mood. The ketone body composition can be encapsulated, incorporated into a microemulsion or into liposomes, agglomerated, processed using masking/flavoring technologies, and/or otherwise processed so as to improve taste and/or reduce organoleptic reactions from the non-human mammal. Example non-human animals include dogs, cats, horses, cattle, sheep, and pigs.

Pet food compositions, and particularly, pet food compositions comprising a botanical component are disclosed herein. In accordance with a first aspect, provided is a pet food composition that includes an effective amount of a plurality of botanical ingredients selected from cinnamon, green tea, pomegranate, ginger, lime peel, tulsi, and a combination of two or more thereof.

Pet food compositions, and particularly, pet food compositions comprising a botanical component are disclosed herein. In accordance with a first aspect, provided is a pet food composition that includes an effective amount of a plurality of botanical ingredients selected from cinnamon, green tea, pomegranate, ginger, lime peel, tulsi, and a combination of two or more thereof.

Methods for preventing feedlot bovine respiratory diseases employing mirtazapine as pre-shipment treatments are disclosed. Compositions are further disclosed. Beneficially, the methods and compositions provide safe and cost-effective management of a costly disease.

Methods for preventing feedlot bovine respiratory diseases employing mirtazapine as pre-shipment treatments are disclosed. Compositions are further disclosed. Beneficially, the methods and compositions provide safe and cost-effective management of a costly disease.

Embodiments herein relate to compositions herein can include one or more of a tomato extract, a rhubarb extract, a garlic extract, a cashew shell composition, and a saponin composition, wherein the composition prevents or reduces methanogenesis in animals. Embodiments herein also relate to compositions including one or more of glycoalkaloids, saponins, anthraquinones, anacardic acid, and allicin and methods for using the same for mitigating methanogenesis in animals. In an embodiment, a composition can include glycoalkaloids, such as α-tomatine, that can prevent methanogenesis. In an embodiment, a method of processing animal feed is included. In an embodiment, a method of treating an animal to reduce methanogenesis is included. Other embodiments are also included herein.